Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2022-05-18 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the three months ended March 31, 2022 and 2021. It contains detailed discussion of the company's operations, financial condition, results of operations, accounting policies, forward-looking statements, and strategic overview. The document references interim unaudited condensed consolidated financial statements prepared under IAS 34, which is the standard for interim financial reporting. The length of the document (15,000 characters) and the detailed content indicate it is a substantive financial report rather than a brief announcement or certification. The MD&A is a management report explaining financial results and business trends for a quarterly period, which fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-05-18 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Unaudited Condensed Consolidated Financial Statements' for the three months ended March 31, 2022 and 2021, indicating it is a financial report covering a quarterly period. It contains detailed financial statements including statements of financial position, comprehensive income, cash flows, and changes in shareholders' equity, along with notes to the financial statements. The document is approximately 15,000 characters long, which is substantial and contains actual financial data and analysis. The presence of management responsibility statements and compliance with IAS 34 (Interim Financial Reporting) further confirms this is an interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-05-18 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a press release dated May 18, 2022, announcing BioSyent Inc.'s financial results for the first quarter ended March 31, 2022. It includes detailed financial highlights such as net revenues, EBITDA, net income, EPS, and shareholders' equity. It also contains interim unaudited condensed consolidated financial statements of comprehensive income and financial position for Q1 2022 and Q1 2021. The document explicitly states it is reporting on the quarterly financial results and includes substantive financial data and analysis for a period shorter than a full fiscal year. The presence of detailed financial statements and management commentary confirms this is an Interim / Quarterly Report rather than a brief earnings release or an announcement of a report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2022
2022-05-18 English
News release - English.pdf
Regulatory Filings
2022-05-10 English
News release - English.pdf
Regulatory Filings
2022-05-02 English
News release - English.pdf
Investor Presentation Classification · 85% confidence The document is a press release announcing that BioSyent Inc. will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference. It includes details about the presentation date, time, and location, as well as a brief company overview and contact information. There is no financial data, no detailed investor presentation content, and no report attached or referenced as being published. The document is short (2790 characters) and serves as an announcement of an upcoming investor presentation event rather than the presentation itself. Therefore, the most appropriate classification is Investor Presentation (IP) since it relates to a presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included, the announcement is about the presentation event itself, which fits best under IP rather than RPA or RNS.
2022-04-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.